News

  • 3 November 2016

    InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod will be granted by the United States Patent and Trademark Office (USPTO). The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy.

  • 28 October 2016

    GALWAY, Ireland, Oct. 28, 2016—4Tech Inc., a privately held clinical-stage company that is developingthe world’s first transcatheter device, TriCinch™, for repair of the Tricuspid heart valve, today announced that it has elected William (“Bill”) A. Hawkins as Chairman, effective immediately. Hawkins was previously Chairman and CEO of Medtronic from 2008—2011, which he joined in 2002 as Senior Vice President and President of Medtronic Vascular.

  • 27 October 2016

    Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies (mAbs) for pre-emptive and post-infection treatment of serious infectious diseases, today announced data from a prospective epidemiology study of the progression of Staphylococcus aureus airway colonization to pneumonia and the impact of antibiotics in mechanically ventilated intensive care unit (ICU) patients. The data demonstrate that S. aureus-active antibiotics did not significantly prevent or reduce heavy S. aureus colonization and did not halt progression to pneumonia. These results will be presented in a poster session at IDWeek 2016 in New Orleans on Friday, October 28.

  • 18 October 2016

     Additional analyses of data from COLLECT – a clinical study of InDex Pharmaceuticals Holding AB’s (publ) lead drug candidate cobitolimod for the treatment of moderate to severe active ulcerative colitis – was orally presented and met with great interest at the United European Gastroenterology Week (UEGW) 2016 in Vienna.

  • 12 October 2016

    Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, infectious diseases and autoimmune diseases, today announces the appointment of Paul Fry as Chief Financial Officer.